Importance Patients with cancer have an increased risk of severe disease and mortality from
COVID-19, as the disease and antineoplastic therapy cause reduced vaccine …

mRNA vaccines have evolved as promising cancer therapies. These vaccines can encode
tumor-allied antigens, thus enabling personalized treatment approaches. They can also …

Importance It has become common practice to offer immunocompromised patients with
hematologic cancers a third COVID-19 vaccination dose, but data substantiating this are …

Importance The SARS-CoV-2 variant B. 1.1. 529 (Omicron) escapes neutralizing antibodies
elicited after COVID-19 vaccination, while T-cell responses might be better conserved. It is …

Individuals with hematologic malignancies are at increased risk for severe coronavirus
disease 2019 (COVID-19), yet profound analyses of COVID-19 vaccine-induced immunity …

Patients with chronic lymphocytic leukemia (CLL) or monoclonal B-lymphocytosis (MBL)
have impaired response to COVID-19 vaccination. A total of 258 patients (215 with CLL and …

Background Patients with hematologic malignancies have impaired humoral immunity
secondary to their malignancy and its treatment, placing them at risk of severe coronavirus …

Background Patients living with cancer are at a significantly increased risk of morbidity and
mortality after infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV …

In this retrospective international multicenter study, we describe the clinical characteristics
and outcomes of patients with chronic lymphocytic leukemia (CLL) and related disorders …

Patients with hematologic malignancies (HM) have demonstrated impaired immune
responses following SARS-CoV-2 vaccination. Factors associated with poor immunogenicity …